Cargando…

First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development

Dose selection for “first in children” trials often relies on scaling of the pharmacokinetics from adults to children. Commonly used approaches are physiologically-based pharmacokinetic modeling (PBPK) and allometric scaling (AS) in combination with maturation of clearance for early life. In this in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strougo, Ashley, Eissing, Thomas, Yassen, Ashraf, Willmann, Stefan, Danhof, Meindert, Freijer, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2012
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306781/ https://www.ncbi.nlm.nih.gov/pubmed/22311388 http://dx.doi.org/10.1007/s10928-012-9241-9

Ejemplares similares

Pharmacokinetic Modeling of Non-Linear Brain Distribution of Fluvoxamine in the Rat
por: Geldof, Marian, et al.
Publicado: (2007)

Pharmacokinetic–Pharmacodynamic Modeling of the Effectiveness and Safety of Buprenorphine and Fentanyl in Rats
por: Yassen, Ashraf, et al.
Publicado: (2007)

Application of Physiologically‐Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin
por: Willmann, Stefan, et al.
Publicado: (2019)

Extensions to the Visual Predictive Check to facilitate model performance evaluation
por: Post, Teun M., et al.
Publicado: (2008)

Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance
por: Dickschen, Kristin, et al.
Publicado: (2012)

Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals
por: Schlender, Jan-Frederik, et al.
Publicado: (2016)

A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life
por: Schlender, Jan-Frederik, et al.
Publicado: (2018)

Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models
por: Danhof, Meindert
Publicado: (2015)

A Detailed Physiologically Based Model to Simulate the Pharmacokinetics and Hormonal Pharmacodynamics of Enalapril on the Circulating Endocrine Renin-Angiotensin-Aldosterone System
por: Claassen, Karina, et al.
Publicado: (2013)

Application of the Convection–Dispersion Equation to Modelling Oral Drug Absorption
por: Freijer, Jan I., et al.
Publicado: (2006)

Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling
por: Dickschen, Kristin, et al.
Publicado: (2014)

A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim
por: Niederalt, Christoph, et al.
Publicado: (2017)

Predictive Performance of Physiology‐Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small‐Molecule Compounds in Children
por: Ince, Ibrahim, et al.
Publicado: (2021)

Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?
por: Calvier, Elisa A. M., et al.
Publicado: (2016)

Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plague
por: Nguyen, Dung, et al.
Publicado: (2021)

Population pharmacokinetic modeling to facilitate dose selection of tapentadol in the pediatric population
por: Watson, Estelle, et al.
Publicado: (2019)

Systematic Evaluation of the Descriptive and Predictive Performance of Paediatric Morphine Population Models
por: Krekels, Elke H. J., et al.
Publicado: (2010)

The role of population PK–PD modelling in paediatric clinical research
por: De Cock, Roosmarijn F. W., et al.
Publicado: (2010)

A Generic Integrated Physiologically based Whole-body Model of the Glucose-Insulin-Glucagon Regulatory System
por: Schaller, S, et al.
Publicado: (2013)

Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban
por: Willmann, Stefan, et al.
Publicado: (2013)

Coping with time scales in disease systems analysis: application to bone remodeling
por: Schmidt, Stephan, et al.
Publicado: (2011)

Physiologically‐based pharmacokinetic modeling to predict CYP3A4‐mediated drug‐drug interactions of finerenone
por: Wendl, Thomas, et al.
Publicado: (2021)

First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa
por: Thomas, Dirk, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim
por: Basu, Sumit, et al.
Publicado: (2020)

Population Pharmacokinetic Model of the Pregabalin-Sildenafil Interaction in Rats: Application of Simulation to Preclinical PK-PD Study Design
por: Bender, Gregor, et al.
Publicado: (2009)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

Predicting Drug Concentration‐Time Profiles in Multiple CNS Compartments Using a Comprehensive Physiologically‐Based Pharmacokinetic Model
por: Yamamoto, Yumi, et al.
Publicado: (2017)

Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics
por: Adiwidjaja, Jeffry, et al.
Publicado: (2020)

The impact of composite AUC estimates on the prediction of systemic exposure in toxicology experiments
por: Sahota, Tarjinder, et al.
Publicado: (2015)

Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?
por: Germovsek, Eva, et al.
Publicado: (2016)

Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models
por: de Witte, Wilhelmus E. A., et al.
Publicado: (2018)

First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men
por: Nowotny, Bettina, et al.
Publicado: (2022)

Characterizing QT interval prolongation in early clinical development: a case study with methadone
por: Dubois, Vincent F. S., et al.
Publicado: (2017)

Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling of the Dopamine D(2) Receptor Occupancy of Olanzapine in Rats
por: Johnson, Martin, et al.
Publicado: (2011)

Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions
por: Willmann, Stefan, et al.
Publicado: (2021)

Correction to: Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models
por: de Witte, Wilhelmus E. A., et al.
Publicado: (2018)

Modeling of prolactin response following dopamine D(2) receptor antagonists in rats: can it be translated to clinical dosing?
por: Taneja, Amit, et al.
Publicado: (2017)

Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study
por: Willmann, Stefan, et al.
Publicado: (2018)

Population pharmacokinetics and dose optimisation of colecalciferol in paediatric patients with chronic kidney disease
por: Wan, Mandy, et al.
Publicado: (2021)

Pharmacokinetic-Pharmacodynamic Modeling of the D(2) and 5-HT(2A) Receptor Occupancy of Risperidone and Paliperidone in Rats
por: Kozielska, Magdalena, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_qtbmf8as6en3d7k6bns628a1ch